Lenoss Medical closed an oversubscribed series A funding round of $4 million to help accelerate commercialization of its OsteoPearl spinal allograft.
The OsteoPearl biologic allograft is made from 100% cortical bone and is designed to stabilize vertebral compression fractures, according to a May 9 news release. The investment will also expand clinical evidence and support development.
Xcellerant Ventures, Highpoint Ventures, Vodia Capital, RightHill Ventures and other groups were involved with funding.